Açaí seed extract mitigates intestinal and hypothalamic alterations in obese mice

Area of Science:

• Metabolic Health and Gut-Brain Axis Research
• Natural Product Therapeutics
• Obesity Pathophysiology

Background:

• Obesity significantly increases morbidity and mortality by disrupting physiological systems.
• Obesity is linked to metabolic dysfunction, impaired gut barrier integrity, and gut microbiota imbalances.
• The effects of açaí seed extract (ASE) on gut health and gut-hypothalamus communication in obesity are not well understood.

Purpose of the Study:

• To investigate the therapeutic effects of ASE on intestinal and hypothalamic alterations in obesity.
• To compare the efficacy of ASE with Metformin in managing obesity-related health issues.
• To explore ASE's impact on gut microbiota and gut-hypothalamus signaling pathways.

Main Methods:

• Male C57BL/6 mice were fed a high-fat (HF) or standard diet for 14 weeks.
• ASE (300 mg/kg/day) and Metformin (300 mg/kg/day) treatments were administered from week 10 to week 14.
• Evaluated parameters included body weight, lipid profile, glycemic homeostasis, oxidative stress markers (8-isoprostane, NOX-4), intestinal integrity, hypothalamic gene expression, gut microbiota composition, and plasma LPS levels.

Main Results:

• Both ASE and Metformin treatments reduced body weight, improved lipid profiles, and ameliorated hyperglycemia and hyperleptinemia.
• Treatments decreased gut oxidative damage, improved intestinal parameters, and modulated hypothalamic gene expression.
• ASE and Metformin reversed obesity-induced gut dysbiosis, characterized by reduced Proteobacteria and elevated LPS levels.

Conclusions:

• ASE and Metformin are effective strategies against obesity's adverse effects on intestinal health and gut-hypothalamus communication.
• ASE demonstrates potential as a natural product for treating obesity-associated intestinal alterations.
• ASE and Metformin act through distinct mechanisms to improve metabolic and gut health.